Cargando…

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254989/ https://www.ncbi.nlm.nih.gov/pubmed/37290923 http://dx.doi.org/10.1136/jitc-2021-003532corr1

Ejemplares similares

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

Increased Soluble CD137 Levels and CD4+ T‐Cell‐Associated Expression of CD137 in Acute Atherothrombotic Stroke
por: He, Yang, et al.
Publicado: (2018)

Soluble CD137 as a potential biomarker for severe COVID-19
por: Marques, Mariana de Oliveira, et al.
Publicado: (2022)

CD137(+) T-Cells: Protagonists of the Immunotherapy Revolution
por: Ugolini, Alessio, et al.
Publicado: (2021)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
por: Chu, Dinh-Toi, et al.
Publicado: (2019)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Correction: CD137 Facilitates the Resolution of Acute DSS-Induced Colonic Inflammation in Mice
por: Martínez Gómez, Julia M., et al.
Publicado: (2014)

Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
por: Kwon, Byungsuk
Publicado: (2015)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity
por: Choi, Beom K., et al.
Publicado: (2020)

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
por: Luu, Khang, et al.
Publicado: (2021)

The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus
por: Mak, Anselm, et al.
Publicado: (2019)

The Roles of CD137 Signaling in Atherosclerosis
por: Jung, In-Hyuk, et al.
Publicado: (2016)

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
por: Upadhyaya, Punit, et al.
Publicado: (2021)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013)

CD137-CD137L Interaction Regulates Atherosclerosis via Cyclophilin A in Apolipoprotein E-Deficient Mice
por: Li, Yuefeng, et al.
Publicado: (2014)

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
por: Adler, Adam J., et al.
Publicado: (2013)

Soluble CD137 Ameliorates Acute Type 1 Diabetes by Inducing T Cell Anergy
por: Itoh, Arata, et al.
Publicado: (2019)

Correction to: Biores Open Access 2016;5:137–145
Publicado: (2017)

Identification of CD137-Expressing B Cells in Multiple Sclerosis Which Secrete IL-6 Upon Engagement by CD137 Ligand
por: Wong, Hiu Yi, et al.
Publicado: (2020)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

CD137 expression in cancer cells: regulation and significance
por: Glorieux, Christophe, et al.
Publicado: (2019)

Contributions of Costimulatory Molecule CD137 in Endothelial Cells
por: Yuan, Wei, et al.
Publicado: (2021)

The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota
por: Blake, Stephen J., et al.
Publicado: (2021)

Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome
por: Yan, Jinchuan, et al.
Publicado: (2013)

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology
por: Upadhyaya, Punit, et al.
Publicado: (2022)

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
por: Cirella, Assunta, et al.
Publicado: (2023)

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
por: Liu, Guizhong, et al.
Publicado: (2023)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses
por: Hong, Jun P., et al.
Publicado: (2020)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b(+)Gr-1(+) Myeloid-derived Suppressor Cells
por: Lee, Jung-Mi, et al.
Publicado: (2010)

Correction: S137 Phosphorylation of Profilin 1 Is an Important Signaling Event in Breast Cancer Progression
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k6nbll5fsq9tqildufhlk0v9cg